HC Wainwright reaffirmed their buy rating on shares of Entera Bio (NASDAQ:ENTX – Free Report) in a research note released on Tuesday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.
Entera Bio Price Performance
Shares of NASDAQ:ENTX opened at $1.93 on Tuesday. The business’s 50 day simple moving average is $2.19 and its 200-day simple moving average is $2.02. The firm has a market capitalization of $69.07 million, a price-to-earnings ratio of -7.42 and a beta of 1.62. Entera Bio has a 12 month low of $1.31 and a 12 month high of $3.35.
Institutional Investors Weigh In On Entera Bio
Several institutional investors have recently modified their holdings of the company. Perigon Wealth Management LLC purchased a new stake in Entera Bio in the 4th quarter valued at approximately $325,000. Northern Trust Corp purchased a new stake in Entera Bio in the 4th quarter valued at approximately $450,000. Parkman Healthcare Partners LLC lifted its stake in Entera Bio by 2.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after buying an additional 9,558 shares in the last quarter. Finally, Knoll Capital Management LLC lifted its stake in Entera Bio by 51.5% in the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock valued at $12,470,000 after buying an additional 2,000,000 shares in the last quarter. Hedge funds and other institutional investors own 14.11% of the company’s stock.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Featured Stories
- Five stocks we like better than Entera Bio
- Retail Stocks Investing, Explained
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- What is a Death Cross in Stocks?
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
